Jenscare Scientific (HKG:9877) said it expects to generate its first-ever revenue in the year ended Dec. 31, 2025, marking its transition out of the pre-revenue stage following the commercialization of its core products.

The company expects revenue of about 90 million yuan to 92 million yuan, with other income and gains of around 15 million yuan to 18 million yuan, bringing total income to roughly 105 million yuan to 110 million yuan, according to a Monday bourse filing.

Jenscare said revenue was driven mainly by sales of its transcatheter aortic valve replacement system, Ken-Valve, in its first year on the market.

The company added that several of its structural heart interventional products have been used in paid clinical implantations overseas, contributing to revenue generation during the period.